信息搜索
信息关键字：药
  
『查询2022年信息』  『查询2021年信息』  『查询2020年信息』  『查询2019年信息』  『查询2018年信息』  『查询2017年信息』  『查询2016年信息』
『查询2015年信息』  『查询2014年信息』  『查询2013年信息』  『查询2012年信息』  『查询2011年信息』  『查询2010年信息』  『查询2009年信息』

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]

·【机构调研记录】金信基金调研奥普特、海创药业等6只个股（附名单）2023-4-3 11:00:56
·【机构调研记录】汇丰晋信基金调研京新药业、恒华科技等6只个股（附名单）2023-4-3 10:39:14
·【机构调研记录】德邦基金调研京新药业、奥普特等9只个股（附名单）2023-4-3 10:24:23
·多方资金囤货中药材南北药都“冷库爆仓”2023-4-2 19:24:37
·国君策略：四月重视成长扩散，关注TMT+医药的轮动，以及传统领域中的细分成长方向2023-4-2 16:09:20
·年报密集披露多只医药生物股获机构评级敏感肌护肤龙头关注度居首2023-4-2 8:14:24
·马斯克“减肥神药”或再下一城：欧盟将批准其增加新适应症2023-4-1 8:56:59
·益丰药房（603939）3月31日主力资金净卖出254.88万元2023-4-1 8:01:58
·股票行情快报：振东制药（300158）3月31日主力资金净买入140.98万元2023-4-1 5:23:06
·龙翔药业2022年亏损1688万同比亏损增加项目融资成本费用化利息支出增加2023-4-1 2:54:08
·金鸿药业2022年净利2677.59万同比增长22.62%产品销售收入增加2023-4-1 2:06:30
·南方制药2022年净利1208.53万同比增长18.12%新产品销售增加2023-4-1 2:02:12
·“东北药茅”长春高新成绩单如何？2023-3-31 21:58:00
·AI制药遇上“ChatGPT热”，创新药迎新想象？2023-3-31 19:59:21
·丽珠集团：公司注射用伏立康唑及注射用头孢地嗪钠拟中选第八批全国药品集中采购2023-3-31 17:21:14
·第一医药：2022年净利同比增190.49%拟10派1.95元2023-3-31 16:01:01
·三生国健：公司重组人II型肿瘤坏死因子受体-抗体融合蛋白注射液取得药品注册证书2023-3-31 15:56:42
·东北制药净利“暴增”但研发薄弱?“控费”或难维持业绩高增2023-3-31 13:25:55
·东北制药净利增2.5倍完成激励目标272%研发费增92%凭优势品种拓展国际市场2023-3-31 12:51:39
·德源药业去年净利1.21亿可位列北交所第13位国内独家持有坎地氢噻片批准文号企业2023-3-31 12:49:11

分页[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239]